Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 1, 2012, Pages 65-73

  Qu, Aijuan ^a   Shah, Yatrik M ^a,b   Manna, Soumen K ^a   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

atherosclerosis; endothelial function; hypertension; lipids; lipoproteins

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; C57BL 6 MOUSE; CELL INFILTRATION; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE EXACERBATION; DYSLIPIDEMIA; ENDOTHELIUM CELL; GENE EXPRESSION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MALE; MEMBRANE PERMEABILITY; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; BONE MARROW TRANSPLANTATION; CAPILLARY PERMEABILITY; CHOLESTEROL; DIET, ATHEROGENIC; ENDOTHELIAL CELLS; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PPAR GAMMA; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 83655167182     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.239137     Document Type: Article

References (41)

1. Tontonoz P, Spiegelman BM. Fat and beyond: The diverse biology of ppargamma. Annu Rev Biochem. 2008;77:289-312.
2. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptorγligands inhibit development of atherosclerosis in ldl receptor-deficient mice. J Clin Invest. 2000;106: 523-531. (Pubitemid 30666385)
3. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21: 365-371. (Pubitemid 32199117)
4. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein e-knockout mice: Pleiotropic effects on cd36 expression and hdl. Arterioscler Thromb Vasc Biol. 2001;21:372-377. (Pubitemid 32199118)
5. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF. Conditional knockout of macrophage PPARγincreases atherosclerosis in c57bl/6 and low-density lipoprotein receptordeficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1647-1653. (Pubitemid 41098935)
6. Subramanian V, Golledge J, Ijaz T, Bruemmer D, Daugherty A. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPARγ. Circ Res. 2010;107: 953-958.
7. Hamblin M, Chang L, Zhang H, Yang K, Zhang J, Chen YE. Vascular smooth muscle cell peroxisome proliferator-activated receptor-γmediates pioglitazone-reduced vascular lesion formation. Arterioscler Thromb Vasc Biol. 2011;31:352-359.
8. Littlewood TD, Bennett MR. Apoptotic cell death in atherosclerosis. Curr Opin Lipidol. 2003;14:469-475. (Pubitemid 37297301)
9. Tricot O, Mallat Z, Heymes C, Belmin J, Leseche G, Tedgui A. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation. 2000;101:2450-2453. (Pubitemid 30366245)
10. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular en-dothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394-402. (Pubitemid 29409616)
11. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin ii-infused rats: Role of peroxisome proliferator-activated receptor-γ. Circulation. 2002;105: 2296-2302. (Pubitemid 34535341)
12. Wang N, Verna L, Chen NG, Chen J, Li H, Forman BM, Stemerman MB. Constitutive activation of peroxisome proliferator-activated receptor-γsuppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem. 2002;277:34176-34181.
13. Ptasinska A, Wang S, Zhang J, Wesley RA, Danner RL. Nitric oxide activation of peroxisome proliferator-activated receptorγthrough a p38 mapk signaling pathway. FASEB J. 2007;21:950-961. (Pubitemid 46348267)
14. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-γ-mediated effects in the vasculature. Circ Res. 2008;102: 283-294. (Pubitemid 351271648)
15. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 2005;366:1279-1289. (Pubitemid 41416583)
16. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-2471. (Pubitemid 46919772)
17. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB Jr, Gonzalez FJ. Conditional disruption of the peroxisome proliferator-activated receptorβgene in mice results in lowered expression of abca1, abcg1, and apoe in macrophages and reduced cholesterol efflux. Mol Cell Biol. 2002;22: 2607-2619. (Pubitemid 34262983)
18. Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ. PPARγin endothelial cells influences high fat diet-induced hypertension. Am J Hypertens. 2005;18:549-556.
19. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, Michel T, Plutzky J. PPARγin the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest. 2009;119:110-124.
20. Shah YM, Morimura K, Gonzalez FJ. Expression of peroxisome proliferator-activated receptor-γin macrophage suppresses experimentally induced colitis. Am J Physiol Gastrointest Liver Physiol. 2007; 292:G657-G666.
21. Ordovas JM, Osgood D. Preparative isolation of plasma lipoproteins using fast protein liquid chromatography (fplc). Methods Mol Biol. 1998; 110:105-111.
22. Innis-Whitehouse W, Li X, Brown WV, Le NA. An efficient chromatographic system for lipoprotein fractionation using whole plasma. J Lipid Res. 1998;39:679-690. (Pubitemid 28158409)
23. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein e-deficient mice by bone marrow transplantation. Science. 1995;267:1034-1037.
24. Fazio S, Linton MF. Murine bone marrow transplantation as a novel approach to studying the role of macrophages in lipoprotein metabolism and atherogenesis. Trends Cardiovasc Med. 1996;6:58-65. (Pubitemid 26090786)
25. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999;286:2511-2514.
26. Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol. 2007;178:7405-7411. (Pubitemid 46847468)
27. Pascual G, Sullivan AL, Ogawa S, Gamliel A, Perissi V, Rosenfeld MG, Glass CK. Anti-inflammatory and antidiabetic roles of PPARγ. Novartis Found Symp. 2007;286:183-196.
28. Fu P, Birukov KG. Oxidized phospholipids in control of inflammation and endothelial barrier. Transl Res. 2009;153:166-176.
29. Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med. 2009;11:e19.
30. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. (Pubitemid 36019640)
31. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165-197.
32. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Expression and function of ppargamma in rat and human vascular smooth muscle cells. Circulation. 2000;101: 1311-1318. (Pubitemid 30158620)
33. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptorγactivators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83: 1097-1103. (Pubitemid 28533518)
34. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptorγ(PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1998;95:7614-7619.
35. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-171. (Pubitemid 32162909)
36. Tesfamariam B, DeFelice AF. Endothelial injury in the initiation and progression of vascular disorders. Vascul Pharmacol. 2007;46:229-237. (Pubitemid 46127847)
37. Yuen CY, Wong WT, Tian XY, Wong SL, Lau CW, Yu J, Tomlinson B, Yao X, Huang Y. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res. 2011;90:122-129.
38. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235-238. (Pubitemid 30054148)
39. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19:2094-2104. (Pubitemid 29422240)
40. Keen HL, Halabi CM, Beyer AM, de Lange WJ, Liu X, Maeda N, Faraci FM, Casavant TL, Sigmund CD. Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptorγin mouse aorta. Arterioscler Thromb Vasc Biol. 2010;30:518-525.
41. Komarova Y, Malik AB. Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu Rev Physiol. 2010;72:463-493.